3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Head and Neck Neoplasms
1
Head and Neck Carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
Cisplatin
24
pembrolizumab
23
Magnetic Resonance Spectroscopy
19
Specimen Handling
16
Radiotherapy, Intensity-Modulated
12
Carboplatin
12
Cetuximab
11
1,2-diaminocyclohexaneplatinum II citrate
10
Platinum
9
Paclitaxel
9
Radiotherapy
6
Radiation
6
Fluorouracil
6
Biopsy
5
Taxes
4
Nivolumab
4
Docetaxel
4
(225)Ac-DOTA-c(RGDyK)
4
X-Rays
3
Pemetrexed
3
Fluorodeoxyglucose F18
3
reolysin
2
pralsetinib
2
ipatasertib
2
cemiplimab
2
atezolizumab
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Solutions
×
Head & Neck
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled